AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. | AstraZeneca has impressed ...

Contract manufacturing powerhouse Lonza is growing in more ways than one. | Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week that it is ...

After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator.  | After a site visit by FDA ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2026. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key ...

Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations, joining a growing wave of healthcare and life sciences heavyweights turning to Big Tech ...

To help BridgeBio ramp up for the launch of three new medicines, plus approved ATTR-CM med Attruby, Sixth Street and HealthCare Royalty have agreed to invest up to $1 billion in the California biotech ...

A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...

Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...

Orca Bio has jumped into the commercial market with FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. Tuesday, the FDA approved the ...

Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...

Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the ...

The FDA has issued a complete response letter to Unicycive over the “same third-party manufacturing deficiencies that were ...